U.S. Pharmaceuticals & Biotech Breakout Stocks

Bio-Techne

Market Cap: US$11.1b

Develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.

Apogee Therapeutics

Market Cap: US$9.9b

A clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States.

Alkermes

Market Cap: US$9.2b

A biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.

Definium Therapeutics

Market Cap: US$6.0b

A clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders.

Oruka Therapeutics

Market Cap: US$5.5b

A clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.

Viking Therapeutics

Market Cap: US$4.4b

A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

Arcus Biosciences

Market Cap: US$3.9b

A clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.

Vera Therapeutics

Market Cap: US$3.0b

A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.

MBX Biosciences

Market Cap: US$2.5b

A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.

Nurix Therapeutics

Market Cap: US$2.4b

A clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.

SELLAS Life Sciences Group

Market Cap: US$2.3b

A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.

AbCellera Biologics

Market Cap: US$2.3b

Engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.

Palvella Therapeutics

Market Cap: US$2.1b

A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

Precigen

Market Cap: US$2.1b

A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.

AtaiBeckley

Market Cap: US$1.9b

A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.

GH Research

Market Cap: US$1.9b

Together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States.

Monte Rosa Therapeutics

Market Cap: US$1.9b

A clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins.

Absci

Market Cap: US$1.8b

A clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.

Zenas BioPharma

Market Cap: US$1.6b

A clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.

Personalis

Market Cap: US$1.4b

Develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.

Jade Biosciences

Market Cap: US$1.3b

Operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.

Lexicon Pharmaceuticals

Market Cap: US$1.1b

A biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.

Cullinan Therapeutics

Market Cap: US$1.1b

A clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.

Avalo Therapeutics

Market Cap: US$956.7m

A clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States.

Nuvectis Pharma

Market Cap: US$721.2m

A clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.

Achieve Life Sciences

Market Cap: US$618.0m

A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.

4D Molecular Therapeutics

Market Cap: US$606.4m

A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.

Monopar Therapeutics

Market Cap: US$587.3m

A clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.

Myriad Genetics

Market Cap: US$555.4m

A molecular diagnostics and precision medicine company, develops molecular tests.

REGENXBIO

Market Cap: US$541.8m

A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.

Shattuck Labs

Market Cap: US$493.8m

A clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States.

Silence Therapeutics

Market Cap: US$479.0m

A biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.

Fennec Pharmaceuticals

Market Cap: US$382.8m

Operates as a commercial stage biopharmaceutical company in the United States.

Galectin Therapeutics

Market Cap: US$328.6m

A clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer.

ALX Oncology Holdings

Market Cap: US$274.5m

A clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.

Oramed Pharmaceuticals

Market Cap: US$191.1m

Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.